Partner Mike Overly was quoted in a CSO article, “DDoS explained: How distributed denial of service attacks are evolving,” about the growing strength and prevalence of denial-of-service attacks.
Overly said businesses are no longer merely concerned about DDoS attacks on themselves, but about attacks on the vast number of business partners, vendors, and suppliers on whom those businesses rely. “One of the oldest adages in security is that a business is only as secure as its weakest link,” he said. “In today’s environment (as evidenced by recent breaches), that weakest link can be, and frequently is, one of the third parties.”
Overly said businesses are no longer merely concerned about DDoS attacks on themselves, but about attacks on the vast number of business partners, vendors, and suppliers on whom those businesses rely. “One of the oldest adages in security is that a business is only as secure as its weakest link,” he said. “In today’s environment (as evidenced by recent breaches), that weakest link can be, and frequently is, one of the third parties.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”